Title
A research agenda for helminth diseases of humans: Diagnostics for control and elimination programmes
Date Issued
01 April 2012
Access level
open access
Resource Type
review
Author(s)
McCarthy J.S.
Lustigman S.
Yang G.J.
Barakat R.M.
Sripa B.
Willingham A.L.
Prichard R.K.
Basáñez M.G.
Abstract
Diagnostic tools appropriate for undertaking interventions to control helminth infections are key to their success. Many diagnostic tests for helminth infection have unsatisfactory performance characteristics and are not well suited for use in the parasite control programmes that are being increasingly implemented. Although the application of modern laboratory research techniques to improve diagnostics for helminth infection has resulted in some technical advances, uptake has not been uniform. Frequently, pilot or proof of concept studies of promising diagnostic technologies have not been followed by much needed product development, and in many settings diagnosis continues to rely on insensitive and unsatisfactory parasitological or serodiagnostic techniques. In contrast, PCR-based xenomonitoring of arthropod vectors, and use of parasite recombinant proteins as reagents for serodiagnostic tests, have resulted in critical advances in the control of specific helminth parasites. The Disease Reference Group on Helminths Infections (DRG4), established in 2009 by the Special Programme for Research and Training in Tropical Diseases (TDR) was given the mandate to review helminthiases research and identify research priorities and gaps. In this review, the diagnostic technologies relevant to control of helminth infections, either available or in development, are reviewed. Critical gaps are identified and opportunities to improve needed technologies are discussed. © 2012 McCarthy et al.
Volume
6
Issue
4
Language
English
OCDE Knowledge area
Parasitología
Scopus EID
2-s2.0-84859006846
PubMed ID
Source
PLoS Neglected Tropical Diseases
ISSN of the container
19352727
Sponsor(s)
A novel approach to bridging the gap between demonstrating a technically satisfactory diagnostic assay, and bringing the product in question to the market entails the formation of organisations specifically tasked with this mission. The foremost example of such a Product Development and Implementation Partnership (PDIP) is the Foundation for Innovative New Diagnostics (FIND; http://www.finddiagnostics.org ), an organisation that focuses on a small number of diseases including TB, sleeping sickness, and malaria. It is supported by the World Health Organization, the Bill & Melinda Gates Foundation, the European Commission, the Government of The Netherlands, UNITAID, DFID, and others. National Institute of Allergy and Infectious Diseases R01AI078314, U01AI065871
Sources of information: Directorio de Producción Científica Scopus